Purinergic receptor remodelling in circulating and airway cells of patients with progressive fibrotic lung disease
Authors:
- Luke FordeLFLuke Forde
- Debananda GogoiDGDebananda Gogoi
- Rory BairdRBRory Baird
- Mengxin NiuMNMengxin Niu
- Sara Waqas AhmedSASara Waqas Ahmed
- Cormac McCarthyCMCormac McCarthy
- Michael P. KeaneMKMichael P. Keane
- Emer P. ReevesEREmer P. Reeves
- Emmet E. McGrathEMEmmet E. McGrath
Open Access
- 23 July 2026
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
No abstract availableFunding Information
- In support of this work, L.F. acknowledges funding from the RCSI StAR MD Programme in collaboration with Blackrock Health Blackrock Clinic (2023) and Bon Secours Hospital Dublin
This publication has 61 references indexed in Scilit:
- Immune mechanisms in fibrotic interstitial lung diseaseCell, 2024
- Physiologic roles of P2 receptors in leukocytesJournal of Leukocyte Biology, 2022
- Increased Extracellular ATP in Plasma of Rheumatoid Arthritis Patients Activates CD8+T CellsArchives of Medical Research, 2021
- Extracellular adenosine 5′-triphosphate in pulmonary disordersBiochemical Pharmacology, 2021
- Release mechanisms of major DAMPsApoptosis, 2021
- P2X7 Receptor as a Therapeutic Target2016
- Purinergic signalling and immune cellsPurinergic Signalling, 2014
- ATP stimulates Ca2+-waves and gene expression in cultured human pulmonary fibroblastsThe International Journal of Biochemistry & Cell Biology, 2009
- Purinergic signalling in the lung: important in asthma and COPD?Current Opinion in Pharmacology, 2004
- Trypan Blue Exclusion Test of Cell ViabilityCurrent Protocols in Immunology, 1997